Oncology/Hematology

Myeloma

More in Myeloma

Stem-Cell Mobilization Booster Wins FDA Approval for Multiple Myeloma

Motixafortide plus filgrastim increased adequate harvest rate from 9.5% to 67.5%

Sep 11, 2023
FDA APPROVED motixafortide (Aphexda) for use with filgrastim (Neupogen) over a fluorescent image of human stem cells
Microdevices for Glioma; Cervical Adenocarcinoma Test; Language Gaps and Cancer Care

News, features, and commentary about cancer-related issues

Sep 07, 2023
Onco Break over a computer rendering of a cancer cell.
Novel Oral Tx Shows Early Promise in Relapsed/Refractory Myeloma

Mezigdomide led to 41% response rate in heavily pretreated patients

Aug 30, 2023
A computer rendering of multiple myeloma cells in the blood.
Nurse Suspected of Poisoning; Hospital Mask Mandates Return; Congressman's Cancer Dx

Health news and commentary from around the Web gathered by MedPage Today staff

Aug 30, 2023
Morning Break over illustration of a syringe, Covid virus, and DNA helix over a photo of green vegetation.
CMS Blinks in 'Flap' Flap; Biomarker Testing; 'What If' Moment in Cancer Screening

News, features, and commentary about cancer-related issues

Aug 25, 2023
Onco Break over a computer rendering of a cancer cell.
Chemo Shortage Fuels Price Gouging; MDS Misdiagnoses; Risky Accelerated Approvals?

News, features, and commentary about cancer-related issues

Aug 18, 2023
Onco Break over a computer rendering of a cancer cell.
New Bispecific Antibody Nabs Conditional FDA Approval for Myeloma

Elranatamab produced 58% response rate as fifth-line therapy

Aug 15, 2023
FDA APPROVED elranatamab-bcmm (Elrexfio) over a computer rendering of multiple myeloma cells.
First-in-Class Drug Approved for Heavily Pretreated Myeloma

Talquetamab achieved response rate of over 70% in MonumenTAL-1 study

Aug 10, 2023
FDA APPROVED talquetamab (Talvey) over a computer rendering of a spine and multiple myeloma cells
Wildfires and Lung Cancer Survival; Poverty and ALL; Cancer Link to Overseas Service

News, features, and commentary about cancer-related issues

Jul 28, 2023
Onco Break over a computer rendering of a cancer cell.
WHO Links Sweetener to Cancer; Younger-Age CRC Risk; PCOS and Ovarian Cancer

News, features, and commentary about cancer-related issues

Jun 29, 2023
Onco Break over a computer rendering of a cancer cell.
'Redlining' and Cancer Screening; Talzenna OK'd for mCRPC; Genomic Testing Misused

News, features, and commentary about cancer-related issues

Jun 22, 2023
Onco Break over a computer rendering of a cancer cell.
New Agents for Relapsed/Refractory Myeloma Impress in Early-Stage Clinical Trials

High rates of deep, durable response with bispecific antibody, rapidly produced CAR T-cell agents

Jun 05, 2023
ASCO over a photo of McCormick place in Chicago, IL.
CAR-T Tops Standard Care in Heavily Pretreated Lenalidomide-Refractory Myeloma

Ciltacabtagene autoleucel improved progression-free survival versus two standard triplets

Jun 05, 2023
ASCO over a photo of McCormick place in Chicago, IL.
World's Smallest Skin Cancer; Exercise Boosts Immune Cells; Cannabis and Pain Relief

News, features, and commentary about cancer-related issues

May 05, 2023
Onco Break over a computer rendering of a cancer cell.
More in Myeloma

Continuing Medical Education

1.00 CME Credits
Navigating the Evolving Treatment Paradigm for Myelodysplastic Syndromes and Myeloproliferative Neoplasms

1.00 CME Credits
Optimizing Biomarker-Directed Therapy to Advance CRC Care: A Clinical Connections Session

1.00 CME Credits
Advancing the Integration of CAR T-Cell Therapy in Community Oncology Centers: A Transformative Quality Improvement Initiative at a Large Community-Based Network

1.00 CME Credits
Advancing Sustainable Practice Change to Improve TNBC Care in Community Based Settings: Insights From an AON Quality Improvement Initiative

1.00 CME Credits
Advancing Personalized Care in HR+/HER2- and Triple-Negative Breast Cancer

0.50 CME Credits
Clinical Case Challenge: Applying the Latest Evidence to Improve Outcomes in BRAF Mutant Advanced Melanoma

1.00 CME Credits
Current Unmet Needs and Paths to Advance NF1 PN Care

0.50 CME Credits
Navigating the Rapidly Evolving DLBCL Treatment Landscape to Deliver Quality Care